Prostaglandin E2 receptor subtype 2 regulation of scavenger receptor CD36 modulates microglial Aβ42 phagocytosis

American Journal of Pathology

Volumn 185, Issue 1, 2015, Pages 230-239

  Li, Xianwu ^a   Melief, Erica ^a   Postupna, Nadia ^a   Montine, Kathleen S ^a   Keene, C Dirk ^a   Montine, Thomas J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CD36 ANTIGEN; PROSTAGLANDIN E RECEPTOR 2; SCAVENGER RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); NEUROTOXIN; PEPTIDE FRAGMENT; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURFACE; CLEARANCE; CONTROLLED STUDY; HIPPOCAMPUS; MICROGLIA; MOUSE; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; WILD TYPE; ALZHEIMER DISEASE; ANIMAL; ASTROCYTE; BRAIN; C57BL MOUSE; CHEMISTRY; CHO CELL LINE; CRICETULUS; CYTOLOGY; DISEASE MODEL; EMBRYOLOGY; INNATE IMMUNITY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIGENS, CD36; ASTROCYTES; BRAIN; CHO CELLS; CRICETULUS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; IMMUNITY, INNATE; INFUSIONS, INTRAVENTRICULAR; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; NEUROTOXINS; PEPTIDE FRAGMENTS; PHAGOCYTOSIS; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; TOLL-LIKE RECEPTORS;

EID: 84918800415     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2014.09.016     Document Type: Article

References (69)

1. D. Galasko, and T.J. Montine Biomarkers of oxidative damage and inflammation in Alzheimer's disease Biomark Med 4 2010 27 36
2. J.C. Lambert, C.A. Ibrahim-Verbaas, D. Harold, A.C. Naj, R. Sims, and C. Bellenguez Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease Nat Genet 45 2013 1452 1458
3. R. Guerreiro, A. Wojtas, J. Bras, M. Carrasquillo, E. Rogaeva, E. Majounie, C. Cruchaga, C. Sassi, J.S. Kauwe, S. Younkin, L. Hazrati, J. Collinge, J. Pocock, T. Lashley, J. Williams, J.C. Lambert, P. Amouyel, A. Goate, R. Rademakers, K. Morgan, J. Powell, P. St George-Hyslop, A. Singleton, J. Hardy Alzheimer Genetic Analysis Group TREM2 variants in Alzheimer's disease N Engl J Med 368 2013 117 127
4. T. Jonsson, H. Stefansson, S. Steinberg, I. Jonsdottir, P.V. Jonsson, J. Snaedal, S. Bjornsson, J. Huttenlocher, A.I. Levey, J.J. Lah, D. Rujescu, H. Hampel, I. Giegling, O.A. Andreassen, K. Engedal, I. Ulstein, S. Djurovic, C. Ibrahim-Verbaas, A. Hofman, M.A. Ikram, C.M. van Duijn, U. Thorsteinsdottir, A. Kong, and K. Stefansson Variant of TREM2 associated with the risk of Alzheimer's disease N Engl J Med 368 2013 107 116
5. C.L. Hsieh, M. Koike, S.C. Spusta, E.C. Niemi, M. Yenari, M.C. Nakamura, and W.E. Seaman A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia J Neurochem 109 2009 1144 1156
6. P. Forabosco, A. Ramasamy, D. Trabzuni, R. Walker, C. Smith, J. Bras, A.P. Levine, J. Hardy, J.M. Pocock, R. Guerreiro, M.E. Weale, and M. Ryten Insights into TREM2 biology by network analysis of human brain gene expression data Neurobiol Aging 34 2013 2699 2714
7. M.W. Sieber, N. Jaenisch, M. Brehm, M. Guenther, B. Linnartz-Gerlach, H. Neumann, O.W. Witte, and C. Frahm Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice following stroke PLoS One 8 2013 e52982
8. H. Ito, and J.A. Hamerman TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells Eur J Immunol 42 2012 176 185
9. M. Sun, M. Zhu, K. Chen, X. Nie, Q. Deng, L.D. Hazlett, Y. Wu, M. Li, M. Wu, and X. Huang TREM-2 promotes host resistance against Pseudomonas aeruginosa infection by suppressing corneal inflammation via a PI3K/Akt signaling pathway Invest Ophthalmol Vis Sci 54 2013 3451 3462
10. G.P. Lim, F. Yang, T. Chu, P. Chen, W. Beech, B. Teter, T. Tran, O. Ubeda, K.H. Ashe, S.A. Frautschy, and G.M. Cole Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease J Neurosci 20 2000 5709 5714
11. C.A. Szekely, and P.P. Zandi Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence CNS Neurol Disord Drug Targets 9 2010 132 139
12. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, A.M. Fagan, T. Iwatsubo, C.R. Jack Jr., J. Kaye, T.J. Montine, D.C. Park, E.M. Reiman, C.C. Rowe, E. Siemers, Y. Stern, K. Yaffe, M.C. Carrillo, B. Thies, M. Morrison-Bogorad, M.V. Wagster, and C.H. Phelps Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
13. P.S. Aisen, K.A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K.L. Davis, M.R. Farlow, S. Jin, R.G. Thomas, L.J. Thal Alzheimer's Disease Cooperative Study Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial JAMA 289 2003 2819 2826
14. L.J. Thal, S.H. Ferris, L. Kirby, G.A. Block, C.R. Lines, E. Yuen, C. Assaid, M.L. Nessly, B.A. Norman, C.C. Baranak, S.A. Reines Rofecoxib Protocol 078 study group A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment Neuropsychopharmacology 30 2005 1204 1215
15. ADAPT Research Group B.K. Martin, C. Szekely, J. Brandt, S. Piantadosi, J.C. Breitner, S. Craft, D. Evans, R. Green, and M. Mullan Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib Arch Neurol 65 2008 896 905
16. J.J. Hoozemans, R. Veerhuis, J.M. Rozemuller, and P. Eikelenboom Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology CNS Neurol Disord Drug Targets 10 2011 57 67
17. D. Jaturapatporn, M.G. Isaac, J. McCleery, and N. Tabet Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease Cochrane Database Syst Rev 2 2012 Cd006378
18. T.J. Montine, J.A. Sonnen, G. Milne, L.D. Baker, and J.C. Breitner Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT PLoS One 5 2010 e9340
19. C. Babiloni, G.B. Frisoni, C. Del Percio, O. Zanetti, C. Bonomini, E. Cassetta, P. Pasqualetti, C. Miniussi, M. De Rosas, A. Valenzano, G. Cibelli, F. Eusebi, and P.M. Rossini Ibuprofen treatment modifies cortical sources of EEG rhythms in mild Alzheimer's disease Clin Neurophysiol 120 2009 709 718
20. J.C. Breitner, L.D. Baker, T.J. Montine, C.L. Meinert, C.G. Lyketsos, K.H. Ashe, J. Brandt, S. Craft, D.E. Evans, R.C. Green, M.S. Ismail, B.K. Martin, M.J. Mullan, M. Sabbagh, P.N. Tariot ADAPT Research Group Extended results of the Alzheimer's disease anti-inflammatory prevention trial Alzheimers Dement 7 2011 402 411
21. P.J. Cimino, C.D. Keene, R.M. Breyer, K.S. Montine, and T.J. Montine Therapeutic targets in prostaglandin E2 signaling for neurologic disease Curr Med Chem 15 2008 1863 1869
22. J. Shi, Q. Wang, J.U. Johansson, X. Liang, N.S. Woodling, P. Priyam, T.M. Loui, M. Merchant, R.M. Breyer, T.J. Montine, and K. Andreasson Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease Ann Neurol 72 2012 788 798
23. K. Andreasson Emerging roles of PGE2 receptors in models of neurological disease Prostaglandins Other Lipid Mediat 91 2010 104 112
24. T.J. Montine, K.R. Sidell, B.C. Crews, W.R. Markesbery, L.J. Marnett, L.J. Roberts II, and J.D. Morrow Elevated CSF prostaglandin E2 levels in patients with probable AD Neurology 53 1999 1495 1498
25. M. Combrinck, J. Williams, M.A. De Berardinis, D. Warden, M. Puopolo, A.D. Smith, and L. Minghetti Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease J Neurol Neurosurg Psychiatry 77 2006 85 88
26. Y. Akitake, Y. Nakatani, D. Kamei, M. Hosokawa, H. Akatsu, S. Uematsu, S. Akira, I. Kudo, S. Hara, and M. Takahashi Microsomal prostaglandin E synthase-1 is induced in alzheimer's disease and its deletion mitigates alzheimer's disease-like pathology in a mouse model J Neurosci Res 91 2013 909 919
27. F.S. Shie, K.S. Montine, R.M. Breyer, and T.J. Montine Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity Glia 52 2005 70 77
28. F.S. Shie, R.M. Breyer, and T.J. Montine Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity Am J Pathol 166 2005 1163 1172
29. P.J. Cimino, I. Sokal, J. Leverenz, Y. Fukui, and T.J. Montine DOCK2 is a microglial specific regulator of central nervous system innate immunity found in normal and Alzheimer's disease brain Am J Pathol 175 2009 1622 1630
30. C.D. Keene, R.C. Chang, A.H. Lopez-Yglesias, B.R. Shalloway, I. Sokal, X. Li, P.J. Reed, L.M. Keene, K.S. Montine, R.M. Breyer, J.K. Rockhill, and T.J. Montine Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow Am J Pathol 177 2010 346 354
31. J.U. Johansson, S. Pradhan, L.A. Lokteva, N.S. Woodling, N. Ko, H.D. Brown, Q. Wang, C. Loh, E. Cekanaviciute, M. Buckwalter, A.B. Manning-Bog, and K.I. Andreasson Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain microglia J Neurosci 33 2013 16016 16032
32. R.L. Silverstein, and M. Febbraio CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior Sci Signal 2 2009 re3
33. F.J. Sheedy, A. Grebe, K.J. Rayner, P. Kalantari, B. Ramkhelawon, S.B. Carpenter, C.E. Becker, H.N. Ediriweera, A.E. Mullick, D.T. Golenbock, L.M. Stuart, E. Latz, K.A. Fitzgerald, and K.J. Moore CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation Nat Immunol 14 2013 812 820
34. I.S. Coraci, J. Husemann, J.W. Berman, C. Hulette, J.H. Dufour, G.K. Campanella, A.D. Luster, S.C. Silverstein, and J.B. El-Khoury CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils Am J Pathol 160 2002 101 112
35. L. Park, G. Wang, P. Zhou, J. Zhou, R. Pitstick, M.L. Previti, L. Younkin, S.G. Younkin, W.E. Van Nostrand, S. Cho, J. Anrather, G.A. Carlson, and C. Iadecola Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta Proc Natl Acad Sci U S A 108 2011 5063 5068
36. J.B. El Khoury, K.J. Moore, T.K. Means, J. Leung, K. Terada, M. Toft, M.W. Freeman, and A.D. Luster CD36 mediates the innate host response to beta-amyloid J Exp Med 197 2003 1657 1666
37. R. Ricciarelli, C. D'Abramo, J.M. Zingg, L. Giliberto, W. Markesbery, A. Azzi, U.M. Marinari, M.A. Pronzato, and M. Tabaton CD36 overexpression in human brain correlates with beta-amyloid deposition but not with Alzheimer's disease Free Radic Biol Med 36 2004 1018 1024
38. X. Li, E. Cudaback, C.D. Keene, R.M. Breyer, and T.J. Montine Suppressed microglial E prostanoid receptor 1 signaling selectively reduces tumor necrosis factor alpha and interleukin 6 secretion from toll-like receptor 3 activation Glia 59 2011 569 576
39. X. Li, E. Cudaback, R.M. Breyer, K.S. Montine, C.D. Keene, and T.J. Montine Eicosanoid receptor subtype-mediated opposing regulation of TLR-stimulated expression of astrocyte glial-derived neurotrophic factor FASEB J 26 2012 3075 3083
40. M. Abramovitz, M. Adam, Y. Boie, M. Carriere, D. Denis, C. Godbout, S. Lamontagne, C. Rochette, N. Sawyer, N.M. Tremblay, M. Belley, M. Gallant, C. Dufresne, Y. Gareau, R. Ruel, H. Juteau, M. Labelle, N. Ouimet, and K.M. Metters The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs Biochim Biophys Acta 1483 2000 285 293
41. M. Kiriyama, F. Ushikubi, T. Kobayashi, M. Hirata, Y. Sugimoto, and S. Narumiya Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells Br J Pharmacol 122 1997 217 224
42. A.M. Pooler, A.A. Arjona, R.K. Lee, and R.J. Wurtman Prostaglandin E2 regulates amyloid precursor protein expression via the EP2 receptor in cultured rat microglia Neurosci Lett 362 2004 127 130
43. M. Patrizio, M. Colucci, and G. Levi Protein kinase C activation reduces microglial cyclic AMP response to prostaglandin E2 by interfering with EP2 receptors J Neurochem 74 2000 400 405
44. K. Wilkinson, J.D. Boyd, M. Glicksman, K.J. Moore, and J. El Khoury A high content drug screen identifies ursolic acid as an inhibitor of amyloid beta protein interactions with its receptor CD36 J Biol Chem 286 2011 34914 34922
45. O. Kuda, T.A. Pietka, Z. Demianova, E. Kudova, J. Cvacka, J. Kopecky, and N.A. Abumrad Sulfo-N-succinimidyl oleate (SSO) inhibits fatty acid uptake and signaling for intracellular calcium via binding CD36 lysine 164: SSO also inhibits oxidized low density lipoprotein uptake by macrophages J Biol Chem 288 2013 15547 15555
46. E.G. Reed-Geaghan, J.C. Savage, A.G. Hise, and G.E. Landreth CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation J Neurosci 29 2009 11982 11992
47. S.C. Tang, J.D. Lathia, P.K. Selvaraj, D.G. Jo, M.R. Mughal, A. Cheng, D.A. Siler, W.R. Markesbery, T.V. Arumugam, and M.P. Mattson Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal Exp Neurol 213 2008 114 121
48. M.L. Udan, D. Ajit, N.R. Crouse, and M.R. Nichols Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line J Neurochem 104 2008 524 533
49. M. Lotz, S. Ebert, H. Esselmann, A.I. Iliev, M. Prinz, N. Wiazewicz, J. Wiltfang, J. Gerber, and R. Nau Amyloid beta peptide 1-40 enhances the action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures J Neurochem 94 2005 289 298
50. R.A. Coleman, W.L. Smith, and S. Narumiya International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes Pharmacol Rev 46 1994 205 229
51. D.P. De Bono, P. Lumley, M. Been, R. Keery, S.E. Ince, and D.F. Woodings Effect of the specific thromboxane receptor blocking drug AH23848 in patients with angina pectoris Br Heart J 56 1986 509 517
52. J. Jiang, and R. Dingledine Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection Trends Pharmacol Sci 34 2013 413 423
53. F.S. Shie, K.S. Montine, R.M. Breyer, and T.J. Montine Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to neurons Brain Pathol 15 2005 134 138
54. K.R. Wildsmith, M. Holley, J.C. Savage, R. Skerrett, and G.E. Landreth Evidence for impaired amyloid beta clearance in Alzheimer's disease Alzheimers Res Ther 5 2013 33
55. F. Pickford, E. Masliah, M. Britschgi, K. Lucin, R. Narasimhan, P.A. Jaeger, S. Small, B. Spencer, E. Rockenstein, B. Levine, and T. Wyss-Coray The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice J Clin Invest 118 2008 2190 2199
56. K.M. Lucin, C.E. O'Brien, G. Bieri, E. Czirr, K.I. Mosher, R.J. Abbey, D.F. Mastroeni, J. Rogers, B. Spencer, E. Masliah, and T. Wyss-Coray Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer's disease Neuron 79 2013 873 886
57. M. Giunta, A.E. Rigamonti, E. Scarpini, D. Galimberti, S.M. Bonomo, E. Venturelli, E.E. Muller, and S.G. Cella The leukocyte expression of CD36 is low in patients with Alzheimer's disease and mild cognitive impairment Neurobiol Aging 28 2007 515 518
58. L.M. Stuart, S.A. Bell, C.R. Stewart, J.M. Silver, J. Richard, J.L. Goss, A.A. Tseng, A. Zhang, J.B. El Khoury, and K.J. Moore CD36 signals to the actin cytoskeleton and regulates microglial migration via a p130Cas complex J Biol Chem 282 2007 27392 27401
59. C. Zamora, E. Canto, J.C. Nieto, M. Angels Ortiz, C. Juarez, and S. Vidal Functional consequences of CD36 downregulation by TLR signals Cytokine 60 2012 257 265
60. T. Melkamu, D. Squillace, H. Kita, and S.M. O'Grady Regulation of TLR2 expression and function in human airway epithelial cells J Membr Biol 229 2009 101 113
61. S.M. Lehmann, C. Kruger, B. Park, K. Derkow, K. Rosenberger, J. Baumgart, T. Trimbuch, G. Eom, M. Hinz, D. Kaul, P. Habbel, R. Kalin, E. Franzoni, A. Rybak, D. Nguyen, R. Veh, O. Ninnemann, O. Peters, R. Nitsch, F.L. Heppner, D. Golenbock, E. Schott, H.L. Ploegh, F.G. Wulczyn, and S. Lehnardt An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration Nat Neurosci 15 2012 827 835
62. J.F. Boyer, P. Balard, H. Authier, B. Faucon, J. Bernad, B. Mazieres, J.L. Davignon, A. Cantagrel, B. Pipy, and A. Constantin Tumor necrosis factor alpha and adalimumab differentially regulate CD36 expression in human monocytes Arthritis Res Ther 9 2007 R22
63. S.E. Hickman, E.K. Allison, and J. El Khoury Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice J Neurosci 28 2008 8354 8360
64. J. Feng, J. Han, S.F. Pearce, R.L. Silverstein, A.M. Gotto Jr., D.P. Hajjar, and A.C. Nicholson Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma J Lipid Res 41 2000 688 696
65. A. Berry, P. Balard, A. Coste, D. Olagnier, C. Lagane, H. Authier, F. Benoit-Vical, J.C. Lepert, J.P. Seguela, J.F. Magnaval, P. Chambon, D. Metzger, B. Desvergne, W. Wahli, J. Auwerx, and B. Pipy IL-13 induces expression of CD36 in human monocytes through PPARgamma activation Eur J Immunol 37 2007 1642 1652
66. K. Kawahara, M. Suenobu, A. Yoshida, K. Koga, A. Hyodo, H. Ohtsuka, A. Kuniyasu, N. Tamamaki, Y. Sugimoto, and H. Nakayama Intracerebral microinjection of interleukin-4/interleukin-13 reduces beta-amyloid accumulation in the ipsilateral side and improves cognitive deficits in young amyloid precursor protein 23 mice Neuroscience 207 2012 243 260
67. M. Yamanaka, T. Ishikawa, A. Griep, D. Axt, M.P. Kummer, and M.T. Heneka PPARgamma/RXRalpha-induced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice J Neurosci 32 2012 17321 17331
68. M. Kouadir, L. Yang, R. Tan, F. Shi, Y. Lu, S. Zhang, X. Yin, X. Zhou, and D. Zhao CD36 participates in PrP(106-126)-induced activation of microglia PLoS One 7 2012 e30756
69. N.A. Abumrad, M. Ajmal, K. Pothakos, and J.K. Robinson CD36 expression and brain function: does CD36 deficiency impact learning ability? Prostaglandins Other Lipid Mediat 77 2005 77 83